Home
News
Create
Screeners
Insights
Aarti Pharma Labs
723.
45
+15.70
(+2.22%)
Market Cap
₹- Cr
PE Ratio
-
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+2.22%
1M
-14.34%
6M
-22.35%
1Y
+10.47%
5Y
+150.98%
View Company Insights
Latest news about Aarti Pharma Labs
Aarti Pharmalabs Reports 11% Revenue Growth in Q2FY26, Revises EBITDA Growth Guidance
Nov 17, 2025
Aarti Pharma Labs reported a 11% year-on-year revenue growth for Q2FY26, reaching INR 417.00 crores. However, EBITDA declined to INR 75.00 crores from INR 85.00 crores, and PAT decreased to INR 31.00 crores from INR 48.00 crores. The company's Xanthine Derivatives segment contributed 51% to turnover, API and Intermediates 39%, and CDMO-CMO Services 10%. The Atali plant was inaugurated in September, and Xanthine expansion is progressing as planned. Aarti Pharma Labs revised its FY26 EBITDA growth guidance to 8-12% year-on-year, with the CDMO-CMO business expected to exceed earlier projections.
Aarti Pharmalabs Reports Strong Q2 Performance with 11% Revenue Growth
Nov 09, 2025
Aarti Pharma Labs Bolsters Leadership with Two Key Senior Management Appointments
Nov 09, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation